Hitgen, Cancer Research UK's Manchester Institute Enter Licence Agreement in Lung Cancer
February 28, 2017
February 28, 2017
LONDON, Feb. 28 -- Cancer Research UK issued the following news release:
Cancer Research UK, Cancer Research Technology (CRT), the charity's commercial arm, and HitGen Ltd, a privately held biotech company focused on early drug discovery, announced today that they have entered into a licence agreement to develop a novel class of drugs against lung cancer.
The work will be carried out by scientists at Cancer Research UK's Drug Discovery Unit at The University of Manc . . .
Cancer Research UK, Cancer Research Technology (CRT), the charity's commercial arm, and HitGen Ltd, a privately held biotech company focused on early drug discovery, announced today that they have entered into a licence agreement to develop a novel class of drugs against lung cancer.
The work will be carried out by scientists at Cancer Research UK's Drug Discovery Unit at The University of Manc . . .